ライフサイエンスコーパス: QFT

1 QFT conversions occurred in 17/147 participants (11.6%;

2 QFT conversions were defined as baseline IFN-gamma less

3 QFT negative, HIV uninfected young children aged 18-24 w

4 QFT reversion risk was inversely associated with interfe

5 QFT reversions occurred in 2/28 participants (7%) with b

6 QFT reversions were defined as baseline IFN-gamma greate

7 QFT was positive in 208 (70.1%) patients and ATT was ins

8 QFT-GIT implementation for LTBI evaluation in a public h

9 QFT-GIT results should be carefully interpreted, particu

10 QFT-GIT supernatants from 13 people with concordant posi

11 QFT-GIT testing had no impact on treatment initiation or

12 QFT-Plus was considered positive if either antigen tube

13 tions, of which 27 observational studies (17 QFT-GIT and 10 T-SPOT) evaluating 590 human immunodefici

14 IGRA result, tuberculosis incidence was 0.2 (QFT) and 0 (TSPOT) per 100 patient-years when contacts r

15 received preventive chemotherapy versus 1.2 (QFT) and 0.8 (TSPOT) per 100 patient-years in those not

16 te the quantitative relation between day 336 QFT value and subsequent disease risk, and we compared d

17 cted persons (T-SPOT, 52% [95% CI, 40%-63%]; QFT-GIT, 50% [95% CI, 35%-65%]).

18 participants (T-SPOT, 61% [95% CI, 40%-79%]; QFT-GIT, 52% [95% CI, 41%-62%]) and among HIV-infected p

19 Among 91 QFT converters who were given a repeat test, 53 (58%) re

20 The best estimate of a QFT level separating TB-positive and TB-negative patient

21 A conservative definition of a QFT-Plus-positive result yielded a positivity rate of 1.

22 results, and conversion rates with alternate QFT cutoffs.

23 ncident tuberculosis was 8-fold higher among QFT reverters than in participants with all negative QFT

24 ivity (>/=10 mm) ranged from 15% to 42%, and QFT positivity rates ranged from 13% to 20%.

25 lts between QFT and QFT-Plus TB1 (84.8%) and QFT and QFT-Plus TB2 (88.6%) fell within the range of 0.

26 nd TST conversion concordance was higher and QFT reversion rates were lower than reported in low-burd

27 se risk was not significantly increased, and QFT reversion was common, following QFT conversion at in

28 Agreement between TST (10 mm increment) and QFT conversions (>or= 0.70 IU/ml) was 96% (kappa = 0.70)

29 ale sex, and ages of 60 years and older, and QFT-only positive results associated with male sex and a

30 jority of discordant results between QFT and QFT-Plus TB1 (84.8%) and QFT and QFT-Plus TB2 (88.6%) fe

31 een QFT and QFT-Plus TB1 (84.8%) and QFT and QFT-Plus TB2 (88.6%) fell within the range of 0.2 to 0.7

32 3.2) and 3.0% (CI, 1.7 to 4.3) with QFT and QFT-Plus, respectively.

33 al of 989 HCWs were tested with both QFT and QFT-Plus.

34 Half of the participants had TST and QFT performed at additional time points.

35 sed sample of concurrently performed TST and QFT tests in a low tuberculosis incidence population, pr

36 I were generally similar between the TST and QFT-GIT.

37 Annualized QFT and TST conversion risks were 14.0 and 13.0%, respec

38 The QuantiFERON-TB Gold In-Tube assay (QFT) is increasingly being used for latent tuberculosis

39 of serial QuantiFERON-TB gold in-tube assay (QFT) testing on 149 patients with active tuberculosis an

40 cy of the QuantiFERON-TB gold in-tube assay (QFT-GIT) were measured.

41 on of the QuantiFERON-TB Gold in-tube assay (QFT-IT) prior to large-scale implementation at the Stanf

42 ly associated with interferon-gamma value at QFT conversion and was highest with interferon-gamma val

43 risk, and we compared disease rates between QFT strata using a two-sample Poisson test.

44 The majority of discordant results between QFT and QFT-Plus TB1 (84.8%) and QFT and QFT-Plus TB2 (8

45 A total of 989 HCWs were tested with both QFT and QFT-Plus.

46 was 4.4% as measured by the TST and 4.8% by QFT-GIT, corresponding to 12,398,000 and 13,628,000 indi

47 ositive for 125 (5.2%) by TST, 118 (4.9%) by QFT-GIT, and 144 (6.0%) by T-SPOT.

48 ordance for 15 of 170 (8.8%) participants by QFT-GIT and for 19 of 151 (12.6%) by T-SPOT when blood w

49 rs (HCWs) at a single U.S. center to compare QFT-Plus to QuantiFERON-TB Gold in-tube (QFT).

50 es for exposure to tuberculosis and compared QFT-GIT and TST performance in risk groups adjusting dem

51 By contrast, QFT conversion at very high interferon-gamma values (>4.

52 ollow-up testing, of 11 HCWs with discordant QFT-Plus results, 90.9% (10/11) had a negative QFT resul

53 ict case definitions were used that excluded QFT results.

54 sed, and QFT reversion was common, following QFT conversion at interferon-gamma values up to 10 times

55 For QFT converters, the TB incidence rate (all cases) was 1.

56 nd 21 of 2,293 (0.9%) for TST (P < 0.001 for QFT-GIT vs. TST and for T-SPOT vs. TST; P = 0.005 for QF

57 s. TST and for T-SPOT vs. TST; P = 0.005 for QFT-GIT vs. T-SPOT).

58 he study period were 138 of 2,263 (6.1%) for QFT-GIT, 177 of 2,137 (8.3%) for T-SPOT, and 21 of 2,293

59 ment over the reported rates of 5 to 40% for QFT-IT.

60 2%) for T-SPOT and 60% (95% CI, 34%-82%) for QFT-GIT.

61 (0.32% [95% CI, 0.03-1.14]) was observed for QFT nonconverters.

62 rculin skin test (TST), QuantiFERON-TB Gold (QFT-G), and T-SPOT.TB.

63 uggestive of ocular TB, 267 patients who had QFT and complete data were evaluated.

64 A significantly higher QFT cutoff value is needed to match the historical TST c

65 However, QFT conversion at interferon-gamma values higher than 4.

66 The threshold between TB and non-TB in QFT values was implausibly low and removing QFT from the

67 A detailed analysis of indeterminate QFT-GIT assay results is presented.

68 When longitudinal QFT data were analyzed in a cross-sectional manner, the

69 d the QFT results from HCWs with two or more QFT tests performed between June 2008 and July 2010 at a

70 A total of 9,153 HCWs with two or more QFT tests were included in the analysis.

71 T-Plus results, 90.9% (10/11) had a negative QFT result.

72 rters than in participants with all negative QFT results (1.47 vs. 0.18 cases/100 person-years, P = 0

73 No QFT differences were observed between placebo and MVA85A

74 ere independent risk factors for nonpositive QFT-GIT results.

75 Other prominent markers in nonstimulated QFT-GIT supernatants were the complement-3 components C3

76 ffect of incubation delay on the accuracy of QFT-IT remains to be determined.

77 Agreement of QFT with QFT-Plus was high, at 95.6% (95% confidence int

78 ubsequent active tuberculosis disease and of QFT reversion.

79 old for positivity improved comparability of QFT-GIT with TST in the low-risk group (adjusted OR [AOR

80 Concordance of QFT-GIT with TST was low (183/352[52%]).

81 The manufacturer's definition of QFT conversion results in an inflated conversion rate th

82 B) infection, but the programmatic impact of QFT-GIT implementation is largely unknown.

83 We conclude that immediate incubation of QFT-IT tubes is an effective way to minimize indetermina

84 A conservative interpretation of QFT-Plus eliminated nearly all nonreproducible positive

85 sess variables associated with positivity of QFT and tuberculin skin tests.

86 n-born individuals had higher proportions of QFT-GIT positivity (57%) than US-born individuals (36%;

87 o improve the quality and reproducibility of QFT-GIT results.

88 BCHD performed QFT-GIT testing for 375/543 (69%) eligible individuals i

89 TST/QFT); and third, a single-step TST plus QFT-GIT (TST/QFT).

90 ut the accuracy of QuantiFERON-TB Gold-Plus (QFT-Plus) for diagnosis of latent M. tuberculosis infect

91 2,751 (51.4%) and 2,987 (55.8%) had positive QFT and TST results, respectively, at baseline.

92 retrospective analysis of repeating positive QFT assays as a strategy to identify false-positive resu

93 hese individuals, 30 (68%) had true-positive QFT-GIT results.

94 Most individuals in the pre- and post-QFT-GIT periods were referred on the basis of a positive

95 ders for suspected LTBI in the pre- and post-QFT-GIT periods, respectively.

96 ceived a final diagnosis of LTBI in the post-QFT-GIT period (397/567 [70%]) compared to the pre-QFT-G

97 5/543 (69%) eligible individuals in the post-QFT-GIT period, of which 185 (49%) were positive, 178 (4

98 In the post-QFT-GIT period, only 230/399 (58%) of those receiving QF

99 vs. 133/167 [80%], respectively) in the post-QFT-GIT period.

100 T period (397/567 [70%]) compared to the pre-QFT-GIT period (445/452 [98%], p<0.001).

101 Unlike its predecessor, QFT-Plus utilizes two antigen tubes to elicit an immune

102 interferon-gamma release assay (QuantiFERON [QFT]) to test for latent infection.

103 We stratified participants by quantitative QFT result (interferon-gamma <0.35 IU/mL, 0.35-4.00 IU/m

104 eriod, only 230/399 (58%) of those receiving QFT-GIT testing had a final diagnosis of LTBI, while 167

105 Recent QFT conversion was indicative of an approximately eight

106 Among recent QFT converters, the magnitude of the QFT value was stron

107 QFT values was implausibly low and removing QFT from the model made prediction slightly worse.

108 Health Department (BCHD) introduced routine QFT-GIT testing for individuals referred to the TB progr

109 Serial QFT testing of HCWs in North America may result in treme

110 Serial testing using a single QFT with the recommended conversion cutoff (IFN-g > 0.35

111 ndings underscore the need for standardizing QFT-GIT preanalytical practices.

112 Adolescents with converted IGRA status (QFT converters [n = 534]) and randomly chosen adolescent

113 In this study, QFT-IT was performed with samples from healthy volunteer

114 test (TST) and the QuantiFERON-TB Gold test (QFT-GT) to detect latent tuberculosis in newly hired hea

115 p TST plus QuantiFERON-TB Gold In-Tube test (QFT-GIT) (2-step TST/QFT); and third, a single-step TST

116 he TST and QuantiFERON-TB Gold In-Tube test (QFT-GIT).

117 Test specificity was higher for TST than QFT-GIT (99.7% vs 91.4%; P < .0001).

118 We show that QFT results do not offer much value for treatment monito

119 The QFT-G and the T-SPOT.TB tests were more sensitive than t

120 The QFT-G test had a pooled sensitivity of 53% (46%-59%) and

121 The QFT-Plus assay showed a high degree of agreement with QF

122 ent between the tuberculin skin test and the QFT test was moderate (81.06%; kappa coefficient 0.485),

123 itivity for the tuberculin skin test and the QFT test were low in study participants younger than 20

124 We retrospectively evaluated the QFT results from HCWs with two or more QFT tests perform

125 .1-3.0) and 99.9% (95% CI, 99.7-100) for the QFT and 0.7% (95% CI, 0.1-2.6) and 99.7% (95% CI, 99.1-9

126 recent QFT converters, the magnitude of the QFT value was strongly inversely associated with risk of

127 Of the QFT-GIT and T-SPOT converters, 81 of 106 (76.4%) and 91

128 Diagnostic performance of the QFT-GIT assay was evaluated in 44 patients with miliary

129 results were subsequently screened using the QFT-GT.

130 ative result, 4.4% (n = 361) converted their QFT result over 2 years.

131 Study clinicians were not masked to QFT values, but strict case definitions were used that e

132 TST(+)/QFT(-) discordance was associated with age, male sex, bl

133 TST(-)/QFT(+) discordance was associated with older age, previo

134 test sensitivity or specificity of the TST, QFT-G, and TSPOT.TB with regards to determining latent t

135 d third, a single-step TST plus QFT-GIT (TST/QFT).

136 diagnoses decreased with the single-step TST/QFT (26.5%) compared with the 2-step TST (42.5%; P < .00

137 2-step TST (42.5%; P < .001) and 2-step TST/QFT (38.5%; P = .02); the incidence of tuberculosis amon

138 N-TB Gold In-Tube test (QFT-GIT) (2-step TST/QFT); and third, a single-step TST plus QFT-GIT (TST/QFT

139 (LTBI) with the QuantiFERON-TB Gold In-Tube (QFT) assay, which exhibits frequent conversions and reve

140 elation between QuantiFERON-TB Gold In-Tube (QFT) conversion interferon-gamma values and risk of subs

141 rculosis by the QuantiFERON-TB Gold In-Tube (QFT) test or the T-SPOT.TB (TSPOT) were prospectively co

142 culosis (TB) by QuantiFERON-TB Gold In-Tube (QFT) tests using latent class analysis model.

143 o) with TST and QuantiFERON-TB Gold In-Tube (QFT).

144 are QFT-Plus to QuantiFERON-TB Gold in-tube (QFT).

145 performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) and T-SPOT.TB (T-SPOT) among adults with suspec

146 Performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) and tuberculin skin test (TST) has not been com

147 The QuantiFERON-TB Gold In-Tube (QFT-GIT) assay provides suboptimal diagnostic performanc

148 ults from 3,263 QuantiFERON-TB Gold in-tube (QFT-GIT) assays were analyzed to determine the impact of

149 QuantiFERON-TB Gold In-Tube (QFT-GIT) is considered an alternative to the tuberculin

150 roducibility of QuantiFERON-TB Gold In-Tube (QFT-GIT) results for 50 subjects (33 uninfected and 17 i

151 test (TST), the Quantiferon-TB Gold in-tube (QFT-GIT), and the T-SPOT.TB (T-SPOT).

152 QuantiFERON-TB Gold In-Tube (QFT-GIT), T-SPOT.TB (T-SPOT), and TST were performed at

153 0% (CI, 0.2 to 1.7; P value of 0.0002 versus QFT-Plus and 0.07 versus QFT).

154 ue of 0.0002 versus QFT-Plus and 0.07 versus QFT).

155 8 (22%) were TST-positive, and 38 (18%) were QFT-positive at baseline.

156 isk of infection was extremely high, whereas QFT and TST conversion concordance was higher and QFT re

157 , 1.0 to 3.2) and 3.0% (CI, 1.7 to 4.3) with QFT and QFT-Plus, respectively.

158 assay showed a high degree of agreement with QFT in U.S.

159 erson-years [95% CI 0.4-1.1]), children with QFT conversion at interferon-gamma values between 0.35-4

160 Among 2512 young children with QFT tests done at day 336, 172 (7%) were positive; 87 (7

161 Compared with QFT non-converters (tuberculosis disease incidence 0.7 p

162 Agreement of QFT with QFT-Plus was high, at 95.6% (95% confidence interval [CI

163 erpretation for students who are tested with QFT-GIT.

164 nt initiation between those with and without QFT-GIT testing (175/230 [76%]) vs. 133/167 [80%], respe

165 in two versions, first with and then without QFT.

166 f LTBI, while 167/168 (99%) of those without QFT-GIT testing were diagnosed with LTBI (p<0.001).

167 remained negative over a period of 2 years (QFT nonconverters [n = 629]) were identified in a cohort